Yep - you are totally correct re the standard deviations and probability. But of course, there is just as much chance that the REAL outcome (ie in a statistically robust population) would be minus 43% (which would put a mighty rocket under the share price) as to be plus 20%.
Probability theory suggests it will be somewhere in between. And, of course, that is the purpose of Phase 3 - to identify just how much more or how much less than 17% is the added benefit of DXB-200.
Statistically, at the 95% confidence level, 55% of the potential outcomes (ie those between minus 43% and minus 10%) will fall within the required efficacy range.
But, of course, statistics do not tell the whole story. Clinical specialists, with a lifetime of experience with drug trials have seen enough encouragement in the Phase 2 (albeit with a small sample) to strongly recommend the Phase 3.
- Forums
- ASX - By Stock
- DXB
- Ann: AGM Presentation
Ann: AGM Presentation, page-52
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
40.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $225.5M |
Open | High | Low | Value | Volume |
40.0¢ | 41.8¢ | 40.0¢ | $776.3K | 1.907M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 111946 | 40.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
41.0¢ | 20706 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 111946 | 0.400 |
5 | 49552 | 0.395 |
10 | 482920 | 0.390 |
2 | 27400 | 0.385 |
5 | 80494 | 0.380 |
Price($) | Vol. | No. |
---|---|---|
0.410 | 20706 | 1 |
0.415 | 20706 | 1 |
0.420 | 23000 | 2 |
0.425 | 50000 | 1 |
0.430 | 159687 | 4 |
Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |